FOLFIRI Chemotherapy Regimen for Colorectal Cancer

Introduction to FOLFIRI Regimen

The FOLFIRI regimen is a combination chemotherapy consisting of leucovorin calcium, fluorouracil, and irinotecan hydrochloride, administered as a biweekly infusional protocol for colorectal cancer treatment, as recommended by the European Society for Medical Oncology 1

The established FOLFIRI protocol includes irinotecan 180 mg/m² IV infusion over 90 minutes on day 1, leucovorin 400 mg/m² IV as a 2-hour infusion on day 1, 5-FU 400 mg/m² IV bolus immediately following leucovorin on day 1, and 5-FU 2,400 mg/m² continuous infusion over 46-48 hours, as outlined by the National Comprehensive Cancer Network 2, 3, 4

FOLFIRI serves as first-line therapy for metastatic colorectal cancer, providing equivalent efficacy to FOLFOX with different toxicity profiles, according to the American Society of Clinical Oncology 2, 3, 4
FOLFIRI is used as second-line therapy after failure of oxaliplatin-based regimens, as recommended by the European Society for Medical Oncology 2, 3
FOLFIRI is used as conversion therapy for initially unresectable metastatic disease to achieve resectability, with a reported response rate of approximately 40-45%, as stated by the National Comprehensive Cancer Network 2, 6, 4

FOLFIRI demonstrates superior outcomes compared to fluoropyrimidine monotherapy, with higher response rates and longer progression-free survival, according to the European Society for Medical Oncology 2, 6, 4
The median overall survival with FOLFIRI approaches 24-30 months when combined with targeted biologics, as reported by the American Society of Clinical Oncology 2, 3

FOLFIRI exhibits a distinct toxicity pattern compared to FOLFOX, with more alopecia and diarrhea but less polyneuropathy, as outlined by the National Comprehensive Cancer Network 2, 3, 4

FOLFIRI and FOLFOX demonstrate equivalent activity as first-line therapy, making the choice dependent on toxicity considerations and planned treatment sequencing, according to the European Society for Medical Oncology 2, 3, 4
The triplet regimen FOLFOXIRI shows improved outcomes in selected patients but remains controversial due to increased toxicity, as stated by the American Society of Clinical Oncology 2, 3

Infusional 5-FU regimens are less toxic than bolus regimens and should be preferentially used, as recommended by the National Comprehensive Cancer Network 2, 6, 4
Chemotherapy orders must specify 24-hour units to prevent medication errors, according to the American Society of Clinical Oncology 5

Treatment continues until disease progression, unacceptable toxicity, or achievement of treatment goals, as outlined by the European Society for Medical Oncology 2, 6, 4
Monitor complete blood counts, liver function, and renal function before each cycle, as recommended by the National Comprehensive Cancer Network 5